뒤로
Bioatla Inc(BCAB) 가격
BCAB 주가 차트
BCAB 수입
Bioatla Inc
$0.32
0.81%
$0
종가: Jan 16, 16:00:00 GMT-5
$0.31
-1.55%
$0
애프터마켓: Jan 16, 20:00:00 GMT-5
주요 통계
이전 종가
$0.3196
시가
$0.32
일일 범위
$0.3172 - $0.3654
52주 범위
$0.24 - $1.43
거래량
1.7M
평균 거래량
1.8M
EPS(TTM)
-0.57
배당수익률
--
시가총액
$18.6M
BCAB란 무엇인가요?
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.